Technologies rarely advance at a steady and predictable pace, but new platforms and newer ideas are already shaping the future of clinical lab testing. This article from the April 2014 issue highlights a handful of companies that are working to bring new diagnostic technologies to market and improve patient care.
Bio-Rad Laboratories Inc has purchased GnuBIO Inc, a privately held life sciences company that has developed a droplet-based DNA sequencing platform.
NovoPath has introduced a customizable web portal for its NovoPath anatomic pathology laboratory information system, helping customers efficiently comply with new rules requiring labs to provide direct patient access to reports.
Constructed of chemical-resistant, flame-retardant, non-metallic composite resin materials, AireStream fume hoods from Hemco Corp maximize user protection while providing energy savings.
The ABL90 Flex acute care analyzer from Radiometer America measures 17 parameters, including blood gases, electrolytes, metabolites, and CO-oximetry from 65 μL of whole blood.
The Nunclon Sphera from Thermo Scientific offers cancer researchers a non-adherent cell culture surface for the formation of consistent cancer and stem cell spheroids in vitro.
Cerilliant has introduced four Certified Spiking Solutions of the corticosteroids pregnenolone, 17α-hydroxypregnenolone, cortisone, and 11-deoxycorticosterone at concentrations of 100 μg/mL in methanol. These hormones have been shown to serve as biomarkers of pain and as indicators of abnormal hormone production.
For every test that has been accepted for use in clinical laboratories, scores of others have been dropped.
Exclusive partnership between Beckman Coulter Diagnostics and hc1.com will bring innovative healthcare cloud technology to clinical laboratories.
Since last November, when FDA cleared Illumina’s MiSeqDx high-throughput sequencer for diagnostic applications, the potential of next-generation sequencing has captured the imagination of many scientists and laboratorians—and with it their engagement in developing clinical tests based on Illumina’s platforms.
Founded in 2012 in La Jolla, Calif, Electrozyme is endeavoring to become the world leader in the development of printed electrochemical biosensors. The company offers a portfolio of printed biosensors that facilitate high-fidelity amperometric, voltammetric, and potentiometric electrochemical analyses of numerous compounds relevant to the healthcare, environmental sensing, and security monitoring domains.